"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"
BioSpectrum Asia|BioSpectrum Asia May2024
US-based Uvax Bio, LLC, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP platform technology invented by Dr Jiang Zhu of Scripps Research to develop and commercialise prophylactic vaccines for challenging infectious diseases.
Ayesha Siddiqui
"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"

The firm is currently conducting phase 1 trials of its HIV vaccine in Australia. Dr Pedro Garbes, Vice President and Global Medical Lead, Uvax Bio elucidates why the firm has chosen Australia for its phase 1 trial.

What makes Uvax Bio’s technology different from other vaccine technologies?

Esta historia es de la edición BioSpectrum Asia May2024 de BioSpectrum Asia.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.

Esta historia es de la edición BioSpectrum Asia May2024 de BioSpectrum Asia.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.

MÁS HISTORIAS DE BIOSPECTRUM ASIAVer todo
Australia invests $1.89B for health and medical research transformation
BioSpectrum Asia

Australia invests $1.89B for health and medical research transformation

The government is investing in a once in a generation transformation of health and medical research in Australia.

time-read
1 min  |
June 2024
NZ suggests new way to prevent rheumatic heart disease progression
BioSpectrum Asia

NZ suggests new way to prevent rheumatic heart disease progression

A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.

time-read
1 min  |
June 2024
WHO prequalifies Takeda's dengue vaccine
BioSpectrum Asia

WHO prequalifies Takeda's dengue vaccine

A new vaccine for dengue has received prequalification from the World Health Organization (WHO).

time-read
1 min  |
June 2024
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
BioSpectrum Asia

GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs

Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.

time-read
1 min  |
June 2024
HOYA Group to distribute AIassisted lesion detection device in US
BioSpectrum Asia

HOYA Group to distribute AIassisted lesion detection device in US

Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.

time-read
1 min  |
June 2024
Saudi Arabia pledges $500M to protect children from polio
BioSpectrum Asia

Saudi Arabia pledges $500M to protect children from polio

At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).

time-read
1 min  |
June 2024
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
BioSpectrum Asia

Scientists explore use of COVID-19 variant vaccine against other coronaviruses

An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.

time-read
1 min  |
June 2024
How Thai Biotech is Thriving with Innovations
BioSpectrum Asia

How Thai Biotech is Thriving with Innovations

Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.

time-read
2 minutos  |
June 2024
Why multi-use real estate is in demand for life sciences companies
BioSpectrum Asia

Why multi-use real estate is in demand for life sciences companies

India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.

time-read
4 minutos  |
June 2024
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
BioSpectrum Asia

"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"

Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.

time-read
5 minutos  |
June 2024